SAFE-PLASMA Protocol
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT9427-27-SSN-701
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Classification Code
-
Additional Details
Documents1
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a Sources Sought notice regarding a forthcoming contract modification for the SAFE-PLASMA Protocol. This procurement activity is managed by the Portfolio Acquisition Executive for Medical Products, specifically within the Warfighter Protection and Acute Care Project Management Office. The intent is to modify an existing contract with Westat Inc., located at 1600 Research Blvd., Rockville, MD 20850, on a sole-source basis.
The primary purpose of this contract modification is to update the current clinical trial design in alignment with recommendations from the U.S. Food and Drug Administration (FDA). The modification will enable Westat Inc. to conduct a Good Clinical Practices (GCP) compliant clinical trial, a critical step toward securing FDA approval for the EZPLAZ™ product. The scope of work includes revising the clinical trial protocol to ensure full compliance with FDA requirements and overseeing the execution of the trial under rigorous GCP standards.
Key objectives of this procurement include:
- Ensuring the clinical trial design meets the latest FDA recommendations.
- Conducting a GCP-compliant clinical trial to support the regulatory approval process for EZPLAZ™.
- Maintaining adherence to all relevant federal and agency-specific research and development standards.
The contract falls under NAICS code 541715, which covers Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), as defined in the 2022 NAICS version. The place of performance is Maryland, United States.
This notice is classified as a Sources Sought, indicating that the DHA is seeking to identify potential sources or gather information prior to issuing a formal solicitation. However, the intent to proceed on a sole-source basis with Westat Inc. is clearly stated, suggesting limited competition for this modification. There are no set-aside requirements or special considerations mentioned in the notice.
The contracting entity is the Defense Health Agency, a federal office within the Department of Defense. Interested parties or those seeking further information should contact Jamie Diggs at [email protected].
Contractors evaluating this opportunity should note that the requirement is highly specialized, focusing on clinical trial design and execution in accordance with FDA and GCP standards, and is currently intended for a sole-source award to Westat Inc. The opportunity is active, with a response deadline of November 16, 2026. Additional details and any attachments can be accessed via the official SAM.gov listing at https://sam.gov/opp/62847f8a042a4f0380c8e0ff90bb2de7/view.